Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Sienna Diagnostics Inks New Distribution Deal for Bladder Cancer Test

Sienna Diagnostics Inks New Distribution Deal for Bladder Cancer Test

Jan 22, 2019
|
staff reporter

NEW YORK (360Dx) — Sienna Cancer Diagnostics said today that it has signed a South Korean distribution agreement for its bladder cancer diagnostic with Mirax.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In Cancer

  1. Paige Secures Additional $15M, Bringing Total Series B Funding to $70M

  2. Amid Interest Generated by Coronavirus Testing, IPO Window Open for Dx Firms in 2020

    Premium

  3. Presence of cfDNA, CTCs Predicts Recurrence in Triple-Negative Breast Cancer

  4. NCI Researchers Leverage Machine Learning for Accurate, Broader-Scale Cervical Cancer Screening

    Premium

  5. Thermo Fisher Scientific, Chugai Pharmaceutical Sign Companion Diagnostic Agreement for NSCLC

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.